Yahoo! Finance: Drug Manufacturers - Other Industry News

Cardiome to Release Third Quarter Results (PR Newswire)

Fri, 6 Nov 2009 23:00:00 Etc/GMT

ZymoGenetics says restraining orders lifted (at bizjournals.com)

Fri, 6 Nov 2009 22:05:18 Etc/GMT

DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009 (PR Newswire)

Fri, 6 Nov 2009 20:26:00 Etc/GMT

DUSA Pharmaceuticals, Inc. , a dermatology company that is developing and marketing Levulan Photodynamic Therapy and other products focused on patients with common skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Merriman Curhan Ford Investor Summit 2009 on Tuesday, November 10, 2009 at 10:00 a.m.

Endo makes first milestone payment to Bioniche for bladder cancer drug (at bizjournals.com)

Fri, 6 Nov 2009 19:05:17 Etc/GMT

Sucampo Pharmaceuticals Invites Investors to Listen to Webcast of Presentation at Credit Suisse Conference (Business Wire)

Fri, 6 Nov 2009 13:15:00 Etc/GMT

BETHESDA, Md.----Sucampo Pharmaceuticals, Inc. today announced that its presentation at the 2009 Annual Credit Suisse Health Care Conference will be webcast and may be accessed at www.sucampo.com.

Specialty Pharma Stock Picks From David Amsellem Of Piper Jaffray (Wall Street Transcript)

Fri, 6 Nov 2009 13:15:00 Etc/GMT

67 WALL STREET, New York - November 6, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results (PR Newswire)

Fri, 6 Nov 2009 13:00:00 Etc/GMT

Ardea Biosciences, Inc. , a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus , today reported recent accomplishments and financial results for the third quarter and nine months ended September 30, 2009.

ArQule 3Q loss narrows on partnership revenue (AP)

Fri, 6 Nov 2009 12:44:23 Etc/GMT

Biotechnology company ArQule Inc. said Thursday its third-quarter loss narrowed on a boost in partnership payments, with a focus on the potential cancer treatment ARQ 197.

NeurogesX Reports Third Quarter 2009 Results (PR Newswire)

Fri, 6 Nov 2009 12:30:00 Etc/GMT

King Pharmaceuticals to Present at Credit Suisse Healthcare Conference (Business Wire)

Fri, 6 Nov 2009 12:00:00 Etc/GMT

BRISTOL, Tenn.----King Pharmaceuticals, Inc. today announced plans to provide a live webcast of its presentation scheduled for Thursday, November 12, 2009, at 9:00 am Mountain Standard Time , at the Credit Suisse 2009 Healthcare Conference at the Arizona Biltmore Hotel in Phoenix, Arizona.

Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations (Business Wire)

Fri, 6 Nov 2009 12:00:00 Etc/GMT

BRANFORD, Conn.----Neurogen Corporation , a drug development company historically focused on drugs for psychiatric and neurological disorders, today announced financial and operating results for the quarter ended September 30, 2009.

DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results (PR Newswire)

Fri, 6 Nov 2009 11:30:00 Etc/GMT

DUSA Pharmaceuticals, Inc.® , a dermatology company that is developing and marketing Levulan® Photodynamic Therapy and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2009.

Amarin Appoints John F. Thero as Chief Financial Officer (Business Wire)

Fri, 6 Nov 2009 09:15:00 Etc/GMT

DUBLIN----Amarin Corporation plc today announced the appointment of John F. Thero as the Companyâs Chief Financial Officer. In this role, Mr. Thero will have broad responsibility for financial and administrative matters of the Company and be actively involved in corporate development and other strategic and operational matters.

Buy This Cheap Biotech Spec? (at CNBC)

Fri, 6 Nov 2009 02:29:44 Etc/GMT

Cramer's 'Mad Money' Recap: The Rich Are Spending Again (Update 2) (at TheStreet.com)

Thu, 5 Nov 2009 23:31:14 Etc/GMT

A Conversation With King Pharma CEO Brian Markison (at CNBC)

Thu, 5 Nov 2009 22:51:15 Etc/GMT

ZymoGenetics narrows loss, revenue up (at bizjournals.com)

Thu, 5 Nov 2009 22:05:22 Etc/GMT

Somaxon Pharmaceuticals Reports 2009 Third Quarter Financial Results (Business Wire)

Thu, 5 Nov 2009 21:05:00 Etc/GMT

SAN DIEGO----Somaxon Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced financial results for the third quarter ended September 30, 2009.

Sucampo Pharmaceuticals Reports Financial Results for the Third Quarter of 2009 (Business Wire)

Thu, 5 Nov 2009 21:05:00 Etc/GMT

BETHESDA, Md.----Sucampo Pharmaceuticals, Inc. today reported its consolidated financial results for the quarter and nine months ended September 30, 2009.

ArQule relies on cash cushion to maintain drug-development efforts (at bizjournals.com)

Thu, 5 Nov 2009 20:05:37 Etc/GMT